Drug Delivery News and Research RSS Feed - Drug Delivery News and Research

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.
U of G research may lead to novel treatment approaches for late-stage ovarian cancer

U of G research may lead to novel treatment approaches for late-stage ovarian cancer

In a potential breakthrough against ovarian cancer, University of Guelph researchers have discovered how to both shrink tumours and improve drug delivery, allowing for lower doses of chemotherapy and reducing side effects. [More]

New multi-specimen perfusion bioreactor for reliable tissue growth introduced by Bose

Bose Corporation has introduced the 3DCulturePro™ system, a new multi-specimen perfusion bioreactor designed for biologists, biomedical researchers and scientists who require reproducible and reliable tissue growth. The 3DCulturePro system supports cell growth and 3D tissue culture in an easy-to-use, scalable configuration. [More]

Unilife submits 10-Q report for first quarter of FY 2015

Unilife Corporation ("Unilife" or "Company"), a developer and supplier of injectable drug delivery systems, today announced that it has submitted for filing its 10-Q report for the first quarter of Fiscal Year 2015 ending September 30, 2014. [More]
BioInfect 2014 conference explores global anti-microbial agenda

BioInfect 2014 conference explores global anti-microbial agenda

This year’s unique BioInfect conference organised by Bionow, a not for profit membership organisation for the biomedical / life-sciences industry,was a major success. [More]
Liposomes can help prevent bacterial toxins from killing human cells

Liposomes can help prevent bacterial toxins from killing human cells

Published in Nature Biotechnology, the study at the University of Liverpool showed that specially engineered lipid (fat) bodies, called liposomes, can be used to prevent bacterial toxins from killing human cells. [More]
Ipsen receives approval from FDA for new device designed to deliver Somatuline Depot Injection

Ipsen receives approval from FDA for new device designed to deliver Somatuline Depot Injection

Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen, today announced that the U.S. Food and Drug Administration (FDA) has approved a new device to deliver Somatuline Depot (lanreotide). The device has an enhanced, prefilled, low-volume syringe that supports full-dose delivery with no reconstitution requirements. [More]
Impax announces submission of EMA Marketing Authorization Application for IPX066

Impax announces submission of EMA Marketing Authorization Application for IPX066

Impax Laboratories (Netherlands) B.V., a wholly owned subsidiary of Impax Laboratories, Inc. today announced that it has submitted a Marketing Authorization Application for IPX066 to the European Medicines Agency. IPX066 is an investigational extended-release capsule formulation of carbidopa-levodopa for the treatment of idiopathic Parkinson's disease. [More]
Discovery Laboratories reports net loss of $11.3 million for third quarter 2014

Discovery Laboratories reports net loss of $11.3 million for third quarter 2014

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced financial results for the third quarter ended September 30, 2014, as well as recent business updates. [More]
Acino recognized with 2014 Europe Frost & Sullivan Award for Enabling Technology Leadership

Acino recognized with 2014 Europe Frost & Sullivan Award for Enabling Technology Leadership

Based on its recent analysis of the pharmaceutical drug delivery industry, Frost & Sullivan recognizes Acino Pharma AG with the 2014 Europe Frost & Sullivan Award for Enabling Technology Leadership. Acino's expertise in targeted drug release profiles and strong technical know-how in pellet-coating, transdermal therapeutic patches and biodegradable implants has made it the preferred vendor in contract manufacturing. [More]
Hospira launches Paricalcitol Injection

Hospira launches Paricalcitol Injection

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, today announced the launch of Paricalcitol Injection, a generic version of AbbVie's Zemplar. Hospira obtained U.S. Food and Drug Administration approval of paricalcitol on Oct. 21 and launched the product Nov. 1. [More]

Ranbaxy obtains FDA approval to manufacture, market Fenofibrate Capsules USP, 43 mg and 130 mg

Ranbaxy Laboratories Limited announced today that the Company has received approval from the U.S. Food and Drug Administration to manufacture and market Fenofibrate Capsules USP, 43 mg and 130 mg. The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Antara Capsules, 43 and 130 mg, respectively, of Lupin Atlantis. [More]
BD reports quarterly revenues of $2.202B for Q4 2014, provides fiscal 2015 outlook

BD reports quarterly revenues of $2.202B for Q4 2014, provides fiscal 2015 outlook

BD (Becton, Dickinson and Company), a leading global medical technology company, today reported quarterly revenues of $2.202 billion for the fourth fiscal quarter ended September 30, 2014, representing an increase of 4.8 percent from the prior-year period, or 4.6 percent on a foreign currency-neutral basis. [More]
CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended September 30, 2014, and also provided an overview of recent accomplishments by and upcoming milestones for its clinical development programs. [More]
Novel therapeutic approaches to improve thyroid cancer outcomes

Novel therapeutic approaches to improve thyroid cancer outcomes

Novel therapeutic approaches to improve outcomes in thyroid cancer, for example using targeted delivery of cytotoxic drugs to tumor cells, will be among the topics featured in oral and poster presentations delivered at the 84th Annual Meeting of the American Thyroid Association, October 29-November 2, 2014, in Coronado, California. [More]
TWi Pharmaceuticals obtains final ANDA approval for Donepezil Hydrochloride Tablets USP, 23 mg

TWi Pharmaceuticals obtains final ANDA approval for Donepezil Hydrochloride Tablets USP, 23 mg

TWi Pharmaceuticals, Inc. today announced that it has received final approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Donepezil Hydrochloride Tablets USP, 23 mg, the generic equivalent to Eisai Inc.'s Aricept 23mg. [More]
New research suggests that TEM5 protein may be a good target for cancer therapy

New research suggests that TEM5 protein may be a good target for cancer therapy

Do blood vessels that feed tumors differ from other blood vessels? Fourteen years ago, experiments designed to answer that question led to the discovery of several genes that are more active in tumor-associated blood vessels than in normal blood vessels. New research now reveals the normal function of one of those genes and suggests it could be a good target for anticancer drug therapy. [More]
New material advances tissue engineering, drug delivery

New material advances tissue engineering, drug delivery

Researchers at the New York University Polytechnic School of Engineering have broken new ground in the development of proteins that form specialized fibers used in medicine and nanotechnology. For as long as scientists have been able to create new proteins that are capable of self-assembling into fibers, their work has taken place on the nanoscale. For the first time, this achievement has been realized on the microscale—a leap of magnitude in size that presents significant new opportunities for using engineered protein fibers. [More]
Anti-cancer nanomedicines with smaller sizes exhibit enhanced performance in vivo, show studies

Anti-cancer nanomedicines with smaller sizes exhibit enhanced performance in vivo, show studies

Nanomedicines consisting of nanoparticles for targeted drug delivery to specific tissues and cells offer new solutions for cancer diagnosis and therapy. [More]

Highland completes US$25 million offering of Class A Common Shares

Highland Therapeutics Inc., a pharmaceutical company, today announced it has completed a US$25 million offering of Class A Common Shares. The financing was led by a private equity partner that is committed to Highland's long-term success. [More]
Sedasys announces launch of new sedation system in the U.S.

Sedasys announces launch of new sedation system in the U.S.

Sedasys, a Division of Ethicon US, LLC, announced today the U.S. launch of its SEDASYS System, a Computer-Assisted Personalized Sedation (CAPS) system that enables trained physician-led teams to administer minimal-to-moderate propofol sedation to healthy patients undergoing routine colonoscopy or esophagogastroduodenoscopy (EGD) procedures. [More]